Compare Summit Therapeutics Inc (SMMT) vs WEC Energy Group Inc. Common Stock (WEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs WEC Energy Group Inc. Common Stock — how do they compare? Summit Therapeutics Inc trades at $15 (market cap $12.07B), while WEC Energy Group Inc. Common Stock trades at $107.87 (market cap $34.78B). The key difference: WEC Energy Group Inc. Common Stock is far larger — about 2.9× Summit Therapeutics Inc's market cap, and WEC Energy Group Inc. Common Stock pays a 3.57% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and WEC Energy Group Inc. Common Stock for 0 Days on average.
| SMMT | WEC | |
|---|---|---|
Market Cap | $12.07B | $34.78B |
Volume | 4,658,232 | 2,317,952 |
Sector | Health | Utilities |
52-Week High | $26.38 | $118.85 |
52-Week Low | $12.43 | $100.78 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $11.40B | $57.74B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today despite recent positive catalysts including a $2 billion strategic investment from AstraZeneca announced September 28, 2026. The stock shows bullish technical signals with strong institutional support, though fundamentals reflect a pre-revenue biotech with significant losses (-$1.08B net income in 2025) and negative ROE of -192.5%. Recent clinical trial collaborations with major pharma partners highlight the company's promising ivonescimab cancer drug pipeline.
The outlook balances substantial upside potential from AstraZeneca's validation and clinical progress against high execution risks typical of developmental biotechs. With 65% analyst buy ratings and a $29.33 consensus target suggesting 89% upside, the stock offers high-risk/high-reward exposure to innovative cancer therapeutics, dependent on successful drug development and regulatory approvals.
WEC Energy Group trades at $105.87, up 0.92% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $0.91 vs. $0.804 expected) and improving profitability (net margin 16.7%). Recent news highlights growing data center demand as a key growth driver, with the company engaging in large-scale customer discussions for 400-500 megawatt projects.
WEC presents a compelling utility investment with stable cash flows and dividend potential, though faces interest rate sensitivity. Analyst consensus targets $118.33 (12% upside) with majority Hold ratings. Key risks include regulatory pressures and capital expenditure requirements for infrastructure expansion through 2030.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About WEC Energy Group Inc. Common Stock
WEC Energy Group is a Midwest electric and natural gas utility holding company whose subsidiaries, including We Energies and Wisconsin Public Service, deliver electricity and natural gas to customers in Wisconsin, Illinois, Michigan, and Minnesota.
Read more on WEC →
